• Biogen completes Nightstar acquisition pharmatimes
    June 11, 2019
    Biogen has announced that it has completed its acquisition of Sycona’s Nightstar Therapeutics, the clinical-stage gene therapy company, which is focused on adeno-associated virus (AAV) treatments for inherited retinal disorders.
PharmaSources Customer Service